Ionis Pharmaceuticals Archives -

Less than six months after the late-stage failure of tofersen, Biogen and Ionis have suffered further disappointment in

New blow for ALS pipeline as Biogen and Ionis candidate fails Phase 1 trial

https://pharmaphorum.com/news/new-blow-for-als-pipeline-as-biogen-and-ionis-candidate-fails-phase-1-trial/

News/ News/ R&D

Pfizer sees no way forward for Ionis-partnered vupanorsen

Phil Taylor antisense drugs, cardiovascular, Ionis Pharmaceuticals, Pfizer, Regeneron 0 Comment

Pfizer has called time on its alliance with Ionis for cholesterol-lowering therapy vupanorsen, after a review of phase

Pfizer sees no way forward for Ionis-partnered vupanorsen

https://pharmaphorum.com/news/pfizer-sees-no-way-forward-for-ionis-partnered-vupanorsen/

News/ News/ R&D

Biogen looks beyond Spinraza in SMA with Ionis deal

Phil Taylor Biogen, Evrysdi, Ionis Pharmaceuticals, Novartis, rare disease, Roche, spinal muscular atrophy, Spinraza, Zolgensma 0 Comment

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with

Biogen looks beyond Spinraza in SMA with Ionis deal

https://pharmaphorum.com/news/biogen-looks-beyond-spinraza-in-sma-with-ionis-deal/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ R&D

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn deal

Phil Taylor Alnylam Pharmaceuticals, antisense oligonucleotides, AstraZeneca, ATTR amyloidosis, Ionis Pharmaceuticals, partnering, Pfizer 0 Comment

AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn deal

https://pharmaphorum.com/news/az-gets-closer-to-ionis-licensing-amyloidosis-drug-in-3-6bn-deal/

The critical role of the generics sector during the pandemic

News/ News/ R&D

Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?

Phil Taylor antisense drugs, cardiovascular, cholesterol, evinacumab, Ionis Pharmaceuticals, Pfizer, Regeneron 0 Comment

Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed

Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?

https://pharmaphorum.com/news/could-safety-scupper-ionis-pfizers-cholesterol-drug-vupanorsen/

Market Access/ News/ News

NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use

Phil Taylor Akcea Therapeutics, antisense drugs, Familial Chylomicronaemia Syndrome, Ionis Pharmaceuticals, NHS, NICE, rare disease 0 Comment

Patients with the rare disease familial chylomicronemia syndrome (FCS) will be able to access treatment with Akcea’s Waylivra

NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use

https://pharmaphorum.com/news/nice-relents-and-okays-akceas-rare-disease-drug-waylivra-for-nhs-use/

News/ News/ R&D

GSK takes option to license hepatitis B RNA drugs from Ionis

Richard Staines GlaxoSmithKline, Ionis Pharmaceuticals, R&D 0 Comment

GlaxoSmithKline has taken an option to license Ionis’ antisense medicines for people with chronic hepatitis B virus infection

GSK takes option to license hepatitis B RNA drugs from Ionis

https://pharmaphorum.com/news/gsk-takes-option-to-license-hepatitis-b-rna-drugs-from-ionis/

Market Access/ News/ News

Ionis’ FCS drug approved in EU, launch due in Germany

Richard Staines Akcea, Ionis Pharmaceuticals, market access, ultra-rare diseases 0 Comment

Ionis Pharmaceuticals’ RNA-targeted drug Waylivra has been conditionally approved in Europe for the devastating ultra-rare disease Familial Chylomicronemia

Ionis’ FCS drug approved in EU, launch due in Germany

https://pharmaphorum.com/news/ionis-fcs-drug-approved-in-eu-launch-due-in-germany/

News/ News/ R&D

Ionis and Roche to develop RNAi AMD drug in $760m deal

Joy Persaud Ionis Pharmaceuticals, ophthalmology, Roche, wet AMD 0 Comment

Ionis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug

Ionis and Roche to develop RNAi AMD drug in $760m deal

https://pharmaphorum.com/news/ionis-and-roche-to-develop-rnai-amd-drug-in-760m-deal/

Trending

Ionis Pharmaceuticals

Login